Traws Pharma, Inc. , a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
Traws Pharma stock last closed at $1.76, down 11.11% from the previous day, and has decreased 89.51% in one year. It has underperformed other stocks in the Biotechnology industry by 0.12 percentage points. Traws Pharma stock is currently +15.79% from its 52-week low of $1.52, and -90.95% from its 52-week high of $19.44.
At the moment, there are 5.07M TRAW shares outstanding. The market value of TRAW is $8.93M. In the past 24 hours, 286,782 TRAW shares were traded.
You need an online brokerage account in order to access the NASDAQ market and buy TRAW stock.
Based on our experience, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, you need to fill out some personal info so you are able to buy TRAW today.
Now that you've finished signing up on the best stock market app, you need to deposit funds:
Check out the tutorial below to see the process of transferring money into your brokerage account.
After you have chosen the best place to buy Traws Pharma stock, it's absolutely critical to research their stock before you buy, so you actually comprehend the risk and upside.
WallStreetZen was built to help everyday investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on TRAW's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge TRAW's intrinsic value.
You can access additional valuation analysis on TRAW's stock here.
You can dig deeper into what analysts are projecting on the Traws Pharma stock forecast page.
Last year, TRAW revenue was $226.00k. In the last five year, TRAW's revenue has grown by -36.47% per year. This was slower than the Biotechnology industry average of 44.31%.
Dive into TRAW's earnings and revenue performance here.
Over the past year, insiders at TRAW have bought more shares than they have sold.
Werner Cautreels, Chief Executive Officer of TRAW, was the latest TRAW insider to buy. They bought $963.48 worth of TRAW shares on Feb 18, 2025.
Learn more about who owns TRAW stock here.
No, Traws Pharma doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
There are two main order types:
Click the Open button and eToro will place the order.
If you need more help with buying stocks on eToro, watch the how to video below:
Now that you own some shares in TRAW, you'll want to keep up with your investment.
Put TRAW on a watchlist to track the latest developments regarding your TRAW stock.
To reiterate, here are the 6 steps to buy stock in Traws Pharma:
If you are looking for a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep tabs on your investment in Traws Pharma, add TRAW to your watchlist below.